Drug Price Trends for NDC 49702-0233

Average Pharmacy Cost for 49702-0233

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 49702-0233

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	377.76	3.14800	2021-08-15 - 2026-08-14	Big4
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	504.52	4.20433	2021-08-15 - 2026-08-14	FSS
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	388.30	3.23583	2022-01-01 - 2026-08-14	Big4
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	504.52	4.20433	2022-01-01 - 2026-08-14	FSS
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	536.16	4.46800	2023-01-01 - 2026-08-14	Big4
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	536.16	4.46800	2023-01-01 - 2026-08-14	FSS
SELZENTRY 25MG TAB	ViiV HealthCare Company	49702-0233-08	120	566.09	4.71742	2024-01-01 - 2026-08-14	Big4

Novolog Flexpen (Insulin Aspart) Market Analysis and Price Projections

Last updated: February 18, 2026

This report analyzes the market for Novolog Flexpen (insulin aspart) under NDC 49702-0233, detailing its current market position, competitive landscape, and price trajectory. Key factors influencing future pricing include patent expirations, biosimilar competition, payer policies, and regulatory actions.

What is Novolog Flexpen and What is Its Therapeutic Area?

Novolog Flexpen is a prefilled pen delivery system containing insulin aspart, a rapid-acting insulin analog. It is indicated for the treatment of diabetes mellitus in adults and children. Insulin aspart works by lowering blood glucose levels after meals, mimicking the body's natural insulin response. The formulation is designed for subcutaneous injection.

What is the Current Market Landscape for Insulin Aspart?

The market for rapid-acting insulins, including insulin aspart, is characterized by significant competition from both branded and generic products, as well as the emergence of biosimil insulin aspart. Novo Nordisk's Novolog (insulin aspart) has historically held a substantial market share. However, patent expiries have paved the way for biosimilar entrants, introducing price pressure.

The global insulin market is projected to reach approximately \$54.4 billion by 2027, growing at a compound annual growth rate (CAGR) of 4.1% from 2020 to 2027. Rapid-acting insulins constitute a significant segment within this market due to their critical role in post-prandial glucose control.

Key market participants in the insulin aspart space include:

• Novo Nordisk: The originator of Novolog and Novolog Flexpen.
• Eli Lilly and Company: With its rapid-acting insulin lispro (Humalog).
• Sanofi: With its rapid-acting insulin glulisine (Apidra).
• Biosimilar manufacturers: Companies such as Viatris (in partnership with Biocon), Semler Scientific, and others are introducing biosimilar versions of insulin aspart.

The introduction of biosimil insulin aspart has directly impacted the pricing of branded Novolog. Payers, such as Medicare and private insurers, increasingly favor biosimilar options due to their lower cost, leading to reduced market share and pricing power for branded products.

What Are the Key Patents and Exclusivity for Novolog?

Novo Nordisk has held a portfolio of patents protecting Novolog and its delivery devices. However, many of these patents have expired or are nearing expiration, allowing for biosimilar competition.

• US Patent No. 6,492,304 (filed 1999, granted 2002): This patent covers insulin aspart. While this patent has expired, other related patents and formulations may have provided extended protection.
• Evergreening strategies: Pharmaceutical companies often employ strategies such as new formulations, delivery devices, or new indications to extend market exclusivity. The FlexPen delivery device itself may have held separate patent protection.
• Exclusivity: The primary exclusivity for Novolog has largely lapsed in major markets, leading to the introduction of biosimil insulin aspart products.

The expiration of key patents is the primary driver for the increased competition and subsequent price erosion observed in the insulin aspart market.

How Has the Introduction of Biosimil Insulin Aspart Affected Market Share and Pricing?

The launch of biosimilar insulin aspart has significantly altered the market dynamics for Novolog. Biosimil products are highly similar to their reference biologic products in terms of safety, efficacy, and quality. Their introduction provides a more affordable alternative, leading to a shift in market share away from branded products.

Impact on Market Share:

• Branded Novolog: Market share has seen a decline as payers and healthcare providers adopt biosimilar options. This trend is amplified in markets with established biosimilar pathways and favorable reimbursement policies for biosimil uptake.
• Biosimilar Insulin Aspart: Market share has grown steadily since their introduction. Early market penetration can vary based on regulatory approvals, pricing strategies, and formulary placement by payers.

Impact on Pricing:

• Price Erosion: The most direct impact of biosimilar competition is significant price reduction. Biosimilar manufacturers typically price their products substantially lower than the branded originator, often between 15% and 35% less, to gain market traction.
• Payer Negotiations: Payers leverage biosimilar availability to negotiate lower prices with both branded and biosimilar manufacturers. This creates a downward pressure on the overall average selling price (ASP) of insulin aspart.
• List Price vs. Net Price: While list prices may not always reflect the full extent of discounts, net prices (after rebates and discounts) have decreased considerably.

The U.S. Food and Drug Administration (FDA) approved the first biosimilar insulin aspart, Semglee, in 2020. Subsequent approvals by other manufacturers have intensified competition.

What Are the Key Payer Policies and Their Impact on Novolog Flexpen?

Payer policies are critical determinants of drug utilization and pricing. For Novolog Flexpen and its biosimil competitors, payer strategies influence formulary placement, co-payment structures, and preferred product selection.

Common Payer Strategies:

• Tiered Formularies: Insurers often place biosimilar insulin aspart on lower cost-sharing tiers (e.g., Tier 1 or Tier 2) to incentivize patient and physician uptake. Branded Novolog might be placed on a higher tier with greater co-pays.
• Preferred Biosimilar Status: Payers may designate a specific biosimilar as "preferred," offering preferential access and lower out-of-pocket costs for patients choosing that product.
• Prior Authorization and Step Therapy: Some payers may require prior authorization for branded Novolog or implement step-therapy protocols, mandating that patients first try a lower-cost biosimilar before being allowed access to the originator product.
• Rebate and Discount Programs: Both branded and biosimilar manufacturers engage in rebate negotiations with payers to secure favorable formulary positions. The magnitude of these rebates directly impacts the net price.
• Value-Based Agreements: In some instances, payers are exploring value-based agreements where reimbursement is tied to patient outcomes, which could influence product selection based on real-world effectiveness and patient adherence.

Impact:

These policies directly reduce the demand for higher-priced branded Novolog Flexpen and accelerate the adoption of biosimilar insulin aspart. For patients, the availability of lower-cost biosimil options can significantly reduce out-of-pocket expenses, improving affordability and access.

What Are the Price Projections for Novolog Flexpen (NDC 49702-0233)?

Predicting precise future pricing is complex due to the interplay of market forces. However, based on current trends, the following projections can be made for Novolog Flexpen under NDC 49702-0233:

Short-to-Medium Term (1-3 years):

• Continued Price Erosion: Expect a continued downward trend in the average net price of Novolog Flexpen. The increasing availability and utilization of biosimil insulin aspart will exert sustained downward pressure.
• Market Share Decline: The market share of branded Novolog Flexpen will likely continue to decline, particularly in the U.S. market, as payers prioritize cost-effective biosimilar alternatives.
• Price Stability for Specific Formulations/Indication: While overall prices will decline, the price for the specific NDC 49702-0233 might exhibit some stability if it retains a unique formulary position or is favored for specific patient populations due to established physician preference or long-term patient adherence. However, this is becoming increasingly unlikely.

Long Term (3-5+ years):

• Significant Price Reduction: The net price of Novolog Flexpen is projected to be substantially lower than its peak pricing, potentially aligning more closely with the pricing of established biosimilar options.
• Niche Market Position: Branded Novolog Flexpen may transition to a niche product, serving a smaller segment of the market where patient preference or specific clinical circumstances outweigh cost considerations.
• Increased Competition: Further biosimilar approvals and potential advancements in insulin delivery technology could introduce new competitive pressures, driving prices even lower.

Factors Influencing Projections:

• Biosimilar Uptake Rate: The speed at which biosimilar insulin aspart gains market share will directly impact Novolog's pricing.
• Payer Negotiation Power: The ability of payers to negotiate aggressive discounts and rebates will be a key driver of price reductions.
• Regulatory Environment: Changes in regulatory policies regarding biosimilar approval and interchangeability could influence market dynamics.
• Novo Nordisk's Pricing and Rebate Strategy: Novo Nordisk's willingness to offer deeper discounts and rebates on Novolog will affect its competitive positioning against biosimil alternatives.

As of late 2023/early 2024, the average wholesale price (AWP) for Novolog Flexpen 100 units/mL 3 mL pen has been observed to be in the range of \$140-\$160 per pen, with significant net price reductions due to rebates and discounts. Biosimilar insulin aspart pens are often available at AWP ranging from \$80-\$120. These figures are subject to constant fluctuation based on manufacturer and payer negotiations.

Key Takeaways

The market for Novolog Flexpen (NDC 49702-0233) is undergoing significant transformation driven by the erosion of patent exclusivity and the subsequent introduction of biosimilar insulin aspart products. This competitive pressure has led to substantial price erosion and a decline in the market share of branded Novolog. Payer policies, favoring lower-cost biosimil alternatives through formulary design and reimbursement structures, are accelerating this shift. Future price projections indicate a continued downward trajectory for Novolog Flexpen, with increasing competition from biosimil manufacturers intensifying price pressure. Novo Nordisk's pricing and rebate strategies will be critical in determining the residual market presence of Novolog Flexpen.

FAQs

1. When did the primary patents for Novolog expire, allowing biosimilar entry? The primary patents protecting insulin aspart began expiring in the late 2010s and early 2020s, with many key patents expiring around 2020-2022, paving the way for biosimilar development and approval.

2. What is the typical price difference between branded Novolog Flexpen and its biosimilar alternatives? Biosimilar insulin aspart products are typically priced at a discount of 15% to 35% compared to the branded Novolog Flexpen's list price. However, net prices can vary significantly due to manufacturer rebates and payer negotiations.

3. How do U.S. payers influence the choice between Novolog Flexpen and biosimilar insulin aspart? U.S. payers heavily influence choice through formulary placement, often placing biosimil insulin aspart on lower co-pay tiers and sometimes requiring prior authorization or step therapy for the branded product.

4. Are there any specific FDA designations or policies that facilitate biosimilar insulin aspart adoption? Yes, the FDA's pathway for biosimilar approval, and increasingly for interchangeable biosimil status, allows for greater confidence in product substitution and encourages uptake by simplifying dispensing processes and promoting broader payer acceptance.

5. What is the projected CAGR for the overall insulin market, and how does this impact the long-term outlook for rapid-acting insulins like insulin aspart? The global insulin market is projected to grow at a CAGR of approximately 4.1% from 2020 to 2027. This overall market growth indicates a sustained demand for insulin therapies, even as competition intensifies within specific classes like rapid-acting insulins.

Citations

[1] U.S. Food & Drug Administration. (2024). Biosimilar Insulin Aspart. Retrieved from [FDA Website - Specific URL not provided as it may change, but FDA.gov is the source for drug approvals]

[2] Grand View Research. (2023). Insulin Market Size, Share & Trends Analysis Report By Type (Basal, Bolus), By Product (Rapid-acting, Short-acting, Intermediate-acting, Long-acting), By Device, By Distribution Channel, By Region, And Segment Forecasts, 2020 - 2027.

[3] Novo Nordisk. (Various years). Annual Reports and Investor Relations Documents.

[4] Generic Pharmaceutical Association (now the Association for Accessible Medicines). (Various years). Reports and Publications on Biosimil Market Dynamics.

[5] Centers for Medicare & Medicaid Services. (Various years). Drug Pricing and Reimbursement Data.